Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial
Sun Yat-sen University · Sun Yat-sen University Cancer Center · +6 more institutions
Indexed incrossref
Abstract
No abstract available for this paper.
Citation impact
160
total citations
- FWCI
- 40.41
- Percentile
- 100%
- References
- 53
Citations per year
Authors
25- FWFeng WangCorresponding
Sun Yat-sen University, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China
- YJYing Jin
Sun Yat-sen University, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China
- MWMin Wang
Sun Yat-sen University, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China
- HLHui Luo
Sun Yat-sen University, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China
- WFWeijia Fang
First Affiliated Hospital Zhejiang University
Topics & keywords
Topics
Keywords
- Bevacizumab
- Clinical endpoint
- Medicine
- Internal medicine
- Phases of clinical research
- Population
- Colorectal cancer
- Oncology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.